G-CSF or Granulocyte the colony-stimulating factor is as glycoprotein comprising 174 amino acids with a molecular weight of about 20000. It is prepared by recombinant DNA technology and frequently used in the treatment of low blood neutrophils. It is also used in conditions where leukapheresis with augmented white blood cells is observed. It stimulates granulocyte production in bone marrow suppressed by chemotherapy & radiotherapy and reduces infections in cancer patients. It can induce terminal maturing of myeloid leukemia cells, resulting in complete hematologic & cytologic remission, and can suppress self-renewal. It is useful in patients with leukemic relapse or AIDS after allogeneic bone marrow transplantation. Some adverse effects are included chest pain, hair loss, joint pain, and vomiting.
According to the study, “Global G-CSF Biosimilars Market Size study, by Type (Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Blood Disorders, Oncology Diseases, Chronic and Autoimmune Diseases, Growth Hormone Deficiencies) and Regional Forecasts 2018-2025” the key companies operating in the global G-CSF biosimilars markets are Merck & Co., Johnson & Johnson, Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis, GlaxoSmithKline, Sanofi, AstraZeneca, Gilead Science, Bayer, AbbVie, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Cadila Pharmaceuticals, Intas Pharmaceuticals, Lupin Limited, Biocon, Emcure Pharmaceuticals Ltd.
Based on type, the G-CSF biosimilars market is segmented into human growth hormone, monoclonal antibodies, erythropoietin, granulocyte-colony stimulating factor, insulin, and interferon. Based on technology, the market is segmented into Recombinant DNA Technology (rDNA technology), Monoclonal Antibodies (MAb) technology, Nuclear magnetic resonance (NMR) technology, chromatography technology, mass spectrometry, electrophoresis, bioassay, western blotting, and others. Based on the type of manufacturing, the market is segmented into contract manufacturing and in-house manufacturing.
Based on application, the market is segmented into blood disorders (chemotherapy induce anemia, pulmonary embolism, and hemophilia), chronic & autoimmune diseases (diabetes, multiple sclerosis, neutropenia, rheumatoid arthritis (RA), cystic fibrosis, leprosy, and acromegaly) oncology diseases (lungs cancer, breast cancer, cervical cancer, colorectal cancer, prostate cancer, and leukemia), infectious diseases, growth hormone deficiencies and others (osteoporosis and Gaucher disease). The blood disease treatment holds the major share in the market owing to high-priced reference biologics and frequent application. The chronic & autoimmune diseases segment is expected to witness the fastest growth rate due to a change in off-patent scenarios during the forecast period. Based on the distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. In addition, based on end-user, the market is segmented into research institutes, hospitals & clinics, and others. The hospitals & clinics are likely to hold the major share in the market as easy availability for treatment with expert faculties.
The G-CSF biosimilars market is driven by growth in the incidence of chronic diseases, followed by an increase in the aging population, favorable intervention from the developing economies and growth in pressure to reduce healthcare expenditure. However, complications associated with the manufacturing of G-CSF biosimilars may impact the market. Moreover, growth in acceptance due to their cost-effectiveness and patent expiry of biologic products are key opportunities for the market.
Based on geography, the North-American region dominates the G-CSF biosimilars market, followed by European owing to growth in the development of health care infrastructure, favorable reimbursement policies, and growth in products in the pipeline in the region. The Asian-Pacific and North-American regions are estimated to witness a considerable growth rate due to the rise in the prevalence of different ailments over the forecast period.
To Know More, Click On The Link Below:-
Ankur Gupta, Head Marketing & Communications